We are thrilled to announce another significant milestone for our business – the official public launch of our new clinical trial prediction and analytics platform, TrialKey.
You may remember recent announcements covering that we had reached MVP stage for the platform’s core development and we are now delighted to be able to make TrialKey available for all members of the public – offering access in a 6-week free trial to any and all interested parties.
Now LIVE, users can sign up for free at the following link:
We are excited to have reached this milestone and thank our dedicated and passionate development team. They have been working exceptionally hard to increase our platform's predictive capability to above 90%*, optimise the user experience, target the platform for initial use cases and future-proof the technology for scale.
This is a key achievement in our roadmap to commercialisation and, having also just successfully raised additional capital from new and existing investors, we have the required funding to accelerate towards flagship revenue.
We hope you find TrialKey as innovative as we know it to be, and we look forward to hearing your feedback.
About TrialKey
TrialKey aims to solve the significant and varied challenges faced by the clinical trials industry, specifically high trial failure rates, sub-optimal and complex trial design and investment wastage, noting only 10% of pivotal clinical trials succeed, with the average trial costing up to ~$50m.
By harnessing the power of artificial intelligence and leveraging a vast repository of over 400,000 datasets from real-world trials, TrialKey aims to usher in a new era of efficiency in clinical trial design and investment.
How TrialKey works
Drawing from an extensive dataset spanning over 20 years and encompassing front-of-curve AI and machine learning technologies, TrialKey analyses real-world trial data based on over 700 variables and provides users with:
A detailed overview of all high-value information for a particular trial, including from critical manufacturer details to granular trial design factors;
A detailed assessment of trial design quality and probability of successfully completing a current trial stage – to over 90%* accuracy;
Detailed analysis on areas to optimise trial design and execution to enhance current and future success outcomes;
Further analysis of comparable trials from other market participants and analysis of similar trials across a particular therapy area;
In essence, TrialKey delivers tailored, actionable steps to address critical trial challenges, improving the likelihood of success as quickly as possible and at lower costs.
As a testament to its reliability, TrialKey accurately forecasted the success of the Moderna and Pfizer vaccines during the COVID-19 pandemic before their clinical trials concluded. This success underscores TrialKey's potential to empower patients, healthcare professionals, clinical researchers, and investors with the foresight needed for effective decision-making in real-time.
* From January 1, 2017, to December 31, 2022, 4,189 clinical trials were utilized to assess TrialKey's algorithm precision and recall accuracy. The algorithm, trained on over 500 variables starting from the year 2010, was retrained yearly, using the subsequent year's trials as holdout samples from 2017 onwards. This process was iterated 100 times for a comprehensive understanding of its performance distribution. The training set examined more than 65,000 historical trials.
In this holdout dataset:
982 trials were actual positives.
The top 10% of algorithm predictions identified 42.5% of actual positives with over 90% precision.
Extending to the top 20% predictions, more than 80% of trial successes were captured with precision consistently exceeding 90%.
This methodology, combined with the utilization of a model trained on a wide range of variables, provides robust insights into the algorithm's performance over the specified period.
What TrialKey Can Do for You
Whether you are a patient, a concerned caregiver, a doctor, a licensed clinician involved in clinical trials, or a proactive investor, TrialKey caters to your needs:
Patients and caregivers can explore potential treatment options and understand the likelihood of success in clinical trials.
Healthcare professionals can make data-driven decisions and treatment recommendations using TrialKey as a valuable resource.
Clinicians from CROs can identify inefficiencies, streamline workflows, and improve clinical trial designs, ultimately reducing time to market and boosting success rates.
Investors and analysts can independently verify data provided by CROs and pharmaceutical companies, making more informed business decisions.
Join us in our mission to transform the landscape of clinical trials, fostering accelerated and more efficient drug development to enhance medical outcomes for patients around the world.